Patents by Inventor Qui-Lim Choo

Qui-Lim Choo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10335492
    Abstract: Compositions and methods are presented in which recombinant IL-11 is PEGylated to achieve improved half-life in serum while having desirable therapeutic activity and presenting less side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: July 2, 2019
    Assignee: NANSHA BIOLOGICS (HONG KONG) LIMITED
    Inventors: Kuo-Ming Yu, Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
  • Publication number: 20180036418
    Abstract: Compositions and methods are presented in which recombinant IL-11 is PEGylated to achieve improved half-life in serum while having desirable therapeutic activity and presenting less side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.
    Type: Application
    Filed: March 1, 2016
    Publication date: February 8, 2018
    Inventors: Kuo-Ming YU, Qui-Lim CHOO, Manson FOK, Johnson Yiu-Nam LAU
  • Patent number: 8481050
    Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: July 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Qui-Lim Choo, Jang Han, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu
  • Patent number: 8475808
    Abstract: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: July 2, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: William Andrews, David Chien, Qui-Lim Choo, Stephen Coates, Doris Coit, Charles Harrington, Susan Hilt, Michael Houghton, Angelica Medina-Selby, Sergio Pichuantes, Yiu-Lian Fong
  • Publication number: 20110150911
    Abstract: Immunogenic compositions for use in treating, preventing and diagnosing infection caused by the California (CAL) serotype of the genus Bunyavirus, such as La Crosse virus (LACV), are disclosed. Also described are reagents for use in diagnostic assays.
    Type: Application
    Filed: November 19, 2004
    Publication date: June 23, 2011
    Inventors: Qui-Lim Choo, Michael Houghton, Elizabeth Scott, Amy Weiner
  • Publication number: 20100227311
    Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.
    Type: Application
    Filed: August 22, 2007
    Publication date: September 9, 2010
    Inventors: Jang Han, Qui-Lim Choo, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu
  • Patent number: 7790366
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: September 7, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20080318275
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: March 17, 2008
    Publication date: December 25, 2008
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 7429385
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: September 30, 2008
    Assignee: Novartis Vaccines & Diagnostics
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Publication number: 20070092538
    Abstract: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.
    Type: Application
    Filed: May 21, 2004
    Publication date: April 26, 2007
    Inventors: William Andrews, David Chien, Qui-Lim Choo, Stephen Coates, Doris Coit, Charles Harrington, Susan Hilt, Michael Houghton, Angelica Medina-Selby, Sergio Pichuantes
  • Publication number: 20060292556
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Application
    Filed: November 9, 2005
    Publication date: December 28, 2006
    Applicant: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Patent number: 7105303
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: September 12, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 7033805
    Abstract: The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg2+ and Mn2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: April 25, 2006
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Jang Han, Joonho Choe
  • Publication number: 20050202418
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Application
    Filed: December 28, 2004
    Publication date: September 15, 2005
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20050089843
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: October 12, 2004
    Publication date: April 28, 2005
    Inventors: Robert Ralston, Frank Marcus, Kent Thudium, Barbara Gervase, John Hall, Kim Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 6861212
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: March 1, 2005
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20040091851
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: November 12, 2002
    Publication date: May 13, 2004
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20040001854
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Application
    Filed: February 18, 2003
    Publication date: January 1, 2004
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Publication number: 20030232328
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: March 14, 2003
    Publication date: December 18, 2003
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20030162167
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: July 25, 1996
    Publication date: August 28, 2003
    Inventors: MICHAEL HOUGHTON, QUI-LIM CHOO, GEORGE KUO